Literature DB >> 26408673

Chronic Lymphocytic Leukemia: Current Concepts.

Eun-Mi Yu1, Adam Kittai2, Imad A Tabbara3.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, and while in early, asymptomatic stages treatment is not indicated, the threat to the quality of life and increased mortality of patients posed by more advanced-stage disease necessitate therapeutic intervention. Guidelines of when and how to treat are not well-established because CLL is a disease of the elderly and it is important to balance preservation of functional status and control of the disease. Advances in molecular and genetic profiling has led to the ability to identify sub-groups of patients with CLL whose disease may respond to selected therapy. This review discusses current standard therapies in the major sub-groups of CLL based on age and functional status, in both the front-line and relapsed/refractory settings. It also provides a concise review of novel agents that have shown considerable efficacy in CLL. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Chronic lymphocytic leukemia; ibrutinib; idelalisib; ofatumumab; review; rituximab; small-cell lymphoma

Mesh:

Substances:

Year:  2015        PMID: 26408673

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia-like B-cell malignancies.

Authors:  Kristine Niss Arfelt; Line Barington; Tau Benned-Jensen; Valentina Kubale; Alexander L Kovalchuk; Viktorija Daugvilaite; Jan Pravsgaard Christensen; Allan Randrup Thomsen; Kristoffer L Egerod; Maria R Bassi; Katja Spiess; Thue W Schwartz; Hongsheng Wang; Herbert C Morse; Peter J Holst; Mette M Rosenkilde
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

Review 2.  Effects of Oxysterols on Immune Cells and Related Diseases.

Authors:  Fábio Alessandro de Freitas; Débora Levy; Cadiele Oliana Reichert; Edecio Cunha-Neto; Jorge Kalil; Sérgio Paulo Bydlowski
Journal:  Cells       Date:  2022-04-07       Impact factor: 7.666

3.  Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.

Authors:  Valentina Trimarco; Elisa Ave; Monica Facco; Giorgia Chiodin; Federica Frezzato; Veronica Martini; Cristina Gattazzo; Federica Lessi; Carlo Alberto Giorgi; Andrea Visentin; Monica Castelli; Filippo Severin; Renato Zambello; Francesco Piazza; Gianpietro Semenzato; Livio Trentin
Journal:  Oncotarget       Date:  2015-12-08

Review 4.  Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients.

Authors:  Salma M AlDallal
Journal:  Ther Clin Risk Manag       Date:  2017-07-20       Impact factor: 2.423

5.  Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.

Authors:  Kyoko Ito; Joun Lee; Stephanie Chrysanthou; Yilin Zhao; Katherine Josephs; Hiroyo Sato; Julie Teruya-Feldstein; Deyou Zheng; Meelad M Dawlaty; Keisuke Ito
Journal:  Cell Rep       Date:  2019-09-03       Impact factor: 9.423

6.  ZGDHu-1 for cancer therapy.

Authors:  Jinlin Liu; Liannv Qiu; Jun Xia; Sufeng Chen; Xiping Yu; Yonglie Zhou
Journal:  Oncol Lett       Date:  2017-09-28       Impact factor: 2.967

7.  Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study).

Authors:  Róbert Szász; Elvira Altai; Katalin Pál; Péter Dombi; János Iványi; János Jakucs; Natália Jóni; Árpád Illés; Ilona Tárkányi; László Szerafin; Zsolt Nagy; Péter Farkas; Ágnes Nagy; Klára Piukovics; György Ujj; Tamás Schneider
Journal:  Pathol Oncol Res       Date:  2018-10-25       Impact factor: 3.201

8.  Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age.

Authors:  Mark P Little; Richard Wakeford; Lydia B Zablotska; David Borrego; Keith T Griffin; Rodrigue S Allodji; Florent de Vathaire; Choonsik Lee; Alina V Brenner; Jeremy S Miller; David Campbell; Siegal Sadetzki; Michele M Doody; Erik Holmberg; Marie Lundell; Michael Jacob Adams; Benjamin French; Martha S Linet; Amy Berrington de Gonzalez
Journal:  Leukemia       Date:  2021-05-28       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.